staurosporine has been researched along with Myeloproliferative Disorders in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Wahab, O; Barbui, T; Cortes, JE; Gale, RP; Gotlib, J; Hehlmann, R; Khoury, HJ; Koschmieder, S; Mauro, M; Mesa, R; Mughal, TI; Radich, JP; Saglio, G; Saussele, S; Van Etten, RA; Verstovek, S | 1 |
| Barbui, T; Bose, P; Chen, CC; Deininger, MW; Gotlib, J; Kiladjian, JJ; Koschmieder, S; Kucine, N; Mughal, TI; Pemmaraju, N; Radich, JP; Rampal, R; Saglio, G; Valent, P; Van Etten, RA; Verstovsek, S | 1 |
| Ebihara, Y; Hanada, S; Imai, K; Konishi, C; Matsuzaka, E; Mochizuki, S; Nakauchi, H; Otsu, M; Takagi, H; Tsuji, K; Yamamoto, S | 1 |
| Amaral, SM; Boulton, CL; Cools, J; Coutre, SE; Curley, DP; DeAngelo, DJ; Duclos, N; Fabbro, D; Gilliland, DG; Gotlib, J; Griffin, JD; Kutok, JL; Lee, BH; Legare, RD; Manley, PW; Marynen, P; Meyer, T; Neuberg, D; Rowan, R; Stone, RM; Stover, EH; Weisberg, E; Williams, IR | 1 |
| Adelsperger, J; Banerji, L; Chen, J; Coburn, A; Cohen, PS; Cohen, S; Deangelo, DJ; Duclos, N; Fabbro, D; Fletcher, JA; Galinsky, I; Gilliland, DG; Griffin, JD; Huntly, B; Kutok, JL; Lee, BH; Meyer, T; Okabe, R; Roesel, J; Stone, RM; Wadleigh, M; Williams, IR; Xiao, S | 1 |
| Cools, J | 1 |
| Adelsperger, J; Anderson, KC; Chen, J; Coburn, A; Cohen, S; Duclos, N; Fabbro, D; Gilliland, DG; Griffin, JD; Huntly, BJ; Kutok, JL; Lee, BH; Mitsiades, CS; Moore, S; Okabe, R; Williams, IR | 1 |
| Amaral, SM; Anastasiadou, E; Boulton, CL; Curley, DP; Duclos, N; Fabbro, D; Gilliland, DG; Griffin, JD; Huntly, BJ; Joseph, SW; Lee, BH; Williams, IR | 1 |
2 review(s) available for staurosporine and Myeloproliferative Disorders
| Article | Year |
|---|---|
Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.
Topics: Antineoplastic Agents; Calreticulin; Cardiovascular Diseases; Cell Transformation, Neoplastic; Chronic Disease; Congresses as Topic; Epigenesis, Genetic; Fusion Proteins, bcr-abl; Humans; Janus Kinase 2; Mastocytosis, Systemic; Mutation; Myeloproliferative Disorders; Protein Kinase Inhibitors; Remission Induction; Staurosporine; Translational Research, Biomedical | 2018 |
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms.
Topics: Aging; Animals; Congresses as Topic; DNA Mutational Analysis; Humans; Inflammation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Medical Oncology; Mice; Mutation; Myeloproliferative Disorders; Prognosis; Societies, Medical; Staurosporine; Translational Research, Biomedical; United States | 2019 |
6 other study(ies) available for staurosporine and Myeloproliferative Disorders
| Article | Year |
|---|---|
Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1.
Topics: Adolescent; Benzimidazoles; Cells, Cultured; Drug Evaluation, Preclinical; Hematopoiesis; Humans; Imatinib Mesylate; Imidazoles; Induced Pluripotent Stem Cells; Male; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyridazines; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Staurosporine; Translocation, Genetic | 2015 |
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Bone Marrow; Bone Marrow Transplantation; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance; Fusion Proteins, bcr-abl; Genetic Vectors; Humans; Imatinib Mesylate; Immunophenotyping; Mice; Models, Genetic; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Piperazines; Precipitin Tests; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Retroviridae; Spleen; Staurosporine; Time Factors | 2003 |
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
Topics: Animals; Cell Line; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 8; Disease Models, Animal; Female; Genetic Variation; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Middle Aged; Myeloproliferative Disorders; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Fibroblast Growth Factor; Staurosporine; Transformation, Genetic; Translocation, Genetic; Zinc Fingers | 2004 |
The hypereosinophilic syndrome: idiopathic or not, that is the question.
Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 4; Chronic Disease; Clone Cells; Diagnosis, Differential; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Lymphoproliferative Disorders; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Staurosporine; T-Lymphocyte Subsets | 2005 |
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
Topics: Animals; Bone Marrow Transplantation; Cell Line, Tumor; Disease Models, Animal; Growth Inhibitors; Hematologic Neoplasms; Lymphoma, B-Cell; Mice; Multiple Myeloma; Myeloproliferative Disorders; Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 3; Recombinant Fusion Proteins; Staurosporine; Thanatophoric Dysplasia; Transfection | 2005 |
FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.
Topics: Animals; Disease Models, Animal; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia; Lymphoma; Mice; Mice, Transgenic; Mutation; Myeloproliferative Disorders; Phenotype; Promoter Regions, Genetic; Protein Kinase C; Staurosporine | 2005 |